{"id":"double-blind-rifaximin","safety":{"commonSideEffects":[{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rifaximin is a rifamycin antibiotic that selectively inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase. This action prevents the transcription of bacterial DNA into RNA, thereby inhibiting bacterial growth and replication.","oneSentence":"Rifaximin works by inhibiting bacterial RNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:54.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of irritable bowel syndrome with diarrhea (IBS-D)"}]},"trialDetails":[{"nctId":"NCT06223685","phase":"NA","title":"The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin","status":"COMPLETED","sponsor":"Pomeranian Medical University Szczecin","startDate":"2023-04-01","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO","enrollment":129},{"nctId":"NCT06727422","phase":"PHASE2","title":"Efficacy of Rifaximin With NAC in IBS-D","status":"NOT_YET_RECRUITING","sponsor":"Mark Pimentel, MD","startDate":"2025-12-15","conditions":"IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)","enrollment":225},{"nctId":"NCT05297448","phase":"PHASE3","title":"Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-08-03","conditions":"Hepatic Encephalopathy","enrollment":466},{"nctId":"NCT05071716","phase":"PHASE3","title":"Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-04-07","conditions":"Hepatic Encephalopathy","enrollment":524},{"nctId":"NCT06538077","phase":"PHASE4","title":"BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-02-01","conditions":"Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy","enrollment":336},{"nctId":"NCT03069131","phase":"PHASE3","title":"Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2018-06-05","conditions":"Cirrhosis, Ascites, Peritonitis","enrollment":160},{"nctId":"NCT04073290","phase":"PHASE4","title":"Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2020-01-21","conditions":"Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension","enrollment":238},{"nctId":"NCT06630572","phase":"PHASE4","title":"Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes","status":"TERMINATED","sponsor":"University of Roma La Sapienza","startDate":"2021-04-03","conditions":"Liver Cirrhosis, Coagulation Disorder, Platelet Disorder","enrollment":20},{"nctId":"NCT05098028","phase":"PHASE2","title":"Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-03-22","conditions":"Sickle Cell Disease","enrollment":44},{"nctId":"NCT05150587","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea","status":"COMPLETED","sponsor":"Alfasigma S.p.A.","startDate":"2021-10-05","conditions":"Papulopustular Rosacea","enrollment":216},{"nctId":"NCT01846663","phase":"PHASE4","title":"Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-04-03","conditions":"Hepatic Encephalopathy","enrollment":6},{"nctId":"NCT02620007","phase":"PHASE2","title":"Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Crohn Disease, Adherent-invasive E. Coli","enrollment":24},{"nctId":"NCT03780673","phase":"PHASE2, PHASE3","title":"Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2019-01-03","conditions":"Liver Cirrhoses","enrollment":254},{"nctId":"NCT03515044","phase":"PHASE2","title":"Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2018-09-13","conditions":"Overt Hepatic Encephalopathy","enrollment":71},{"nctId":"NCT02498301","phase":"NA","title":"Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2015-11-10","conditions":"Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis","enrollment":449},{"nctId":"NCT01137955","phase":"NA","title":"Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-10","conditions":"Celiac Disease","enrollment":50},{"nctId":"NCT00603616","phase":"PHASE2","title":"Induction of Clinical Response Using Rifaximin in Crohn's Disease","status":"COMPLETED","sponsor":"Scott Lee","startDate":"2008-11","conditions":"Crohn's Disease","enrollment":36},{"nctId":"NCT03469050","phase":"PHASE2, PHASE3","title":"Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2018-07-02","conditions":"Diverticulitis","enrollment":193},{"nctId":"NCT02272868","phase":"PHASE1, PHASE2","title":"Fecal Microbial Transplant in Pediatric Crohn's Disease","status":"TERMINATED","sponsor":"Seattle Children's Hospital","startDate":"2015-01","conditions":"Crohn's Disease","enrollment":7},{"nctId":"NCT03537157","phase":"PHASE2","title":"A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2017-11-16","conditions":"Crohn Disease","enrollment":43},{"nctId":"NCT04128462","phase":"PHASE3","title":"MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function","status":"WITHDRAWN","sponsor":"Mallinckrodt","startDate":"2021-11","conditions":"Hepatic Encephalopathy","enrollment":""},{"nctId":"NCT04118699","phase":"PHASE2","title":"Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial","status":"UNKNOWN","sponsor":"Yokohama City University","startDate":"2019-12-25","conditions":"Chronic Intestinal Pseudo-obstruction","enrollment":12},{"nctId":"NCT00533910","phase":"NA","title":"Rifaximin in Minimal Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","startDate":"2007-10","conditions":"Hepatic Encephalopathy","enrollment":42},{"nctId":"NCT03962283","phase":"PHASE2, PHASE3","title":"Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2019-08-02","conditions":"Small Bowel Disease, Rifaximin","enrollment":78},{"nctId":"NCT02016196","phase":"PHASE3","title":"Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Cirrhosis","enrollment":211},{"nctId":"NCT01866826","phase":"PHASE1, PHASE2","title":"Rifaximin for Chronic Immune Activation in People With HIV","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01-18","conditions":"HIV","enrollment":46},{"nctId":"NCT00742469","phase":"PHASE3","title":"Rifaximin for Prevention of Travellers' Diarrhea","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-06","conditions":"Diarrhea","enrollment":210},{"nctId":"NCT02498418","phase":"PHASE3","title":"Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-01-06","conditions":"Diarrhea","enrollment":739},{"nctId":"NCT00731679","phase":"PHASE3","title":"Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-07","conditions":"Non-Constipation Irritable Bowel Syndrome","enrollment":623},{"nctId":"NCT00724126","phase":"PHASE3","title":"Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-07","conditions":"Non-Constipation Irritable Bowel Syndrome","enrollment":637},{"nctId":"NCT00328380","phase":"PHASE3","title":"Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12","conditions":"Diarrhea","enrollment":660},{"nctId":"NCT00269412","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12","conditions":"Irritable Bowel Syndrome","enrollment":525},{"nctId":"NCT00858988","phase":"NA","title":"Trial of Rifaximin in the Treatment of Tropical Enteropathy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2007-09","conditions":"Tropical Enteropathy","enrollment":147},{"nctId":"NCT01904409","phase":"PHASE2","title":"Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":420},{"nctId":"NCT00269399","phase":"PHASE3","title":"A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12","conditions":"Clostridium Infections, Diarrhea","enrollment":237},{"nctId":"NCT00298038","phase":"PHASE3","title":"A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12-19","conditions":"Hepatic Encephalopathy","enrollment":299},{"nctId":"NCT02240121","phase":"PHASE3","title":"One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2014-08-21","conditions":"Crohn's Disease","enrollment":80},{"nctId":"NCT02240108","phase":"PHASE3","title":"One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2014-10-28","conditions":"Crohn's Disease","enrollment":81},{"nctId":"NCT03911037","phase":"PHASE2, PHASE3","title":"GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2019-05-04","conditions":"Decompensated Cirrhosis of Liver","enrollment":70},{"nctId":"NCT03150459","phase":"PHASE2","title":"Simvastatin Plus Rifaximin in Decompensated Cirrhosis","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2017-07-26","conditions":"Cirrhoses, Liver","enrollment":44},{"nctId":"NCT02920242","phase":"PHASE3","title":"A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.","status":"TERMINATED","sponsor":"Sandoz","startDate":"2016-12-15","conditions":"Travelers' Diarrhea","enrollment":28},{"nctId":"NCT03864978","phase":"PHASE2","title":"Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test","status":"UNKNOWN","sponsor":"Alfasigma S.p.A.","startDate":"2018-06-22","conditions":"Papulopustular Rosacea","enrollment":236},{"nctId":"NCT02280044","phase":"PHASE2, PHASE3","title":"Efficacy of Rifaximin in Preventing Campylobacteriosis","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2014-10","conditions":"Dysentery, Diarrhea, Enteric Campylobacteriosis","enrollment":30},{"nctId":"NCT01543178","phase":"PHASE3","title":"Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-02","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":2583},{"nctId":"NCT02884037","phase":"","title":"Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2012-05","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":50},{"nctId":"NCT01618591","phase":"NA","title":"Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea","status":"TERMINATED","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2012-09","conditions":"Acute Watery Diarrhea, Dysentery/Febrile Diarrhea","enrollment":384},{"nctId":"NCT02019784","phase":"PHASE4","title":"Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2015-01","conditions":"Liver Cirrhosis, Hepatoencephalopathy, Early Fatal Progressive","enrollment":38},{"nctId":"NCT02376972","phase":"PHASE2","title":"Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2015-04","conditions":"BACTERIAL VAGINOSIS","enrollment":392},{"nctId":"NCT01603108","phase":"PHASE2","title":"Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant","status":"UNKNOWN","sponsor":"Columbia University","startDate":"2012-03","conditions":"Hepatitis C","enrollment":59},{"nctId":"NCT00945334","phase":"NA","title":"Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Mark Pimentel, MD","startDate":"2009-08","conditions":"Constipation-predominant Irritable Bowel Syndrome","enrollment":37},{"nctId":"NCT01359228","phase":"PHASE2","title":"Rifaximin Treatment of Papulopustular Rosacea","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2013-04","conditions":"Rosacea","enrollment":""},{"nctId":"NCT02009618","phase":"NA","title":"The Effects of Rifaximin Therapy in Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2013-01","conditions":"IBS","enrollment":500},{"nctId":"NCT00979056","phase":"PHASE3","title":"Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin","status":"COMPLETED","sponsor":"Dr. Philipp Zanger, MD MSc DTM","startDate":"2009-10","conditions":"Diarrhoea","enrollment":258},{"nctId":"NCT01218568","phase":"NA","title":"Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2010-10","conditions":"Hepatic Encephalopathy","enrollment":120},{"nctId":"NCT00281502","phase":"PHASE2","title":"The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Weill Medical College of Cornell University","startDate":"2005-12","conditions":"Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis","enrollment":50},{"nctId":"NCT00528073","phase":"PHASE2","title":"Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease","status":"COMPLETED","sponsor":"Alfasigma S.p.A.","startDate":"2007-09","conditions":"Crohn's Disease","enrollment":410},{"nctId":"NCT00259155","phase":"PHASE2","title":"Rifaximin for the Treatment of Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2003-07","conditions":"Irritable Bowel Syndrome","enrollment":92},{"nctId":"NCT00098384","phase":"PHASE2","title":"Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea","status":"COMPLETED","sponsor":"DuPont, Hurbert L., MD","startDate":"2003-06","conditions":"Diarrhea","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rifaximin"],"phase":"phase_3","status":"active","brandName":"double-blind rifaximin","genericName":"double-blind rifaximin","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifaximin works by inhibiting bacterial RNA synthesis. Used for Treatment of irritable bowel syndrome with diarrhea (IBS-D).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}